OMHE_Projected_Rev=$17Million_Applying_for_FDA_Registration_for_MJ_Based_Pain_Treatment_Medicine OMHE_is_The_Champion_of_6_Pharma_Industries Check Their Website
1) Specialty Pharmacy
2) Regenerative Medicine
4) Skincare Technologies
5) Cannabis Technologies – Another PR is Expected in Few Days!!!
6) Global Wellness OMHE has scientists, R&D Lab, plan and is ready to market/sell Marijuana based Pain treatment therapeutics and medicine. Also, OTCQB upgrade is on the way!
12/05/2017 MMJ Medicine Development & FDA Approval Plan News - Read Here
Based on four decades of exemplary care, Omni Health has started the process of reformulating its most successful proprietary formularies to include cannabidiol (CBD) and commence its FDA Medical Devices registration for topical pain analgesic. It is Omni Health’s intent to capitalize on a significant potential for cannabinoid bio therapeutics to transform the treatment of chronic pain and other debilitating conditions, and bring a product to the market with a strong demand and reimbursable under government payors and major insurance plans.
Simultaneous to the FDA application for this new drug, the Company will commence by manufacturing OTC analgesic creams and ointments containing CBD with rapid absorption and optimal bioavailability profiles. Given the potency of these analgesics, they will be marketed and distributed exclusively to doctors’ offices, clinics, and hospitals to ensure appropriate patient support and product usage. As per the current schedule, it’s anticipated they this product will be introduced to the North American market during Q3 2018. Based on current market trends and competitor analysis, Omni Health projects generating a recurring annual revenue exceeding $7 Million.
“The Global Market for Pain Management will grow from nearly $36.1 Billion in 2017 to $52.0 Billion by 2022 and the Cannabidiol (CBD) market is estimated to grow by 700% by 2020”, concluded Andrey Soloviev, “As such, there is a unique potential for Omni Health to truly seize the day by bringing the first FDA registered CBD pain analgesic to the market”
OMHE PPS Ready to Rise to $1